JAMA Dermatology —The Year in Review, 2025
-
By
-
Kanade Shinkai
-
May 1, 2026
-
0 min
Clinical Report: JAMA Dermatology Highlights and Developments from 2025
Overview
In 2025, JAMA Dermatology evaluated 3413 manuscripts, achieving a 7% acceptance rate. Key performance metrics improved, notably reducing the median time from acceptance to publication to 63 days, enhancing the journal's dissemination of dermatological research.
Background
The continuous rise in manuscript submissions to JAMA Dermatology underscores the growing interest and advancements in dermatological research. With a high impact factor of 11, the journal plays a crucial role in disseminating significant findings that can influence clinical practice. Understanding these developments is essential for healthcare professionals to stay informed about emerging therapies and research in dermatology.
Data Highlights
| Metric | 2024 | 2025 |
|---|---|---|
| Median days from acceptance to publication | 70 | 63 |
| Median receipt-to-rejection time | N/A | 3 days |
| Median receipt to first decision with peer review | N/A | 36 days |
| Median review turnaround time | N/A | 12 days |
Key Findings
- 3413 manuscripts evaluated, with 1242 being research submissions.
- Acceptance rates fell to 7% for both research articles and overall submissions.
- Median time from acceptance to publication decreased from 70 days in 2024 to 63 days in 2025.
- Highest-viewed articles included studies on oral nicotinamide for skin cancer prevention and risk of psoriasiform eruptions with dupilumab.
- Top cited articles addressed the global burden of skin cancer and novel treatments for chronic urticaria.
Clinical Implications
The improvements in publication timelines and the high volume of submissions reflect the dynamic nature of dermatological research. Clinicians should stay updated with the latest findings, particularly regarding new therapies and preventive measures for skin conditions, to enhance patient care.
Conclusion
JAMA Dermatology's advancements in 2025 highlight the journal's commitment to rapid dissemination of critical dermatological research, which is vital for informing clinical practice.
Related Resources & Content
- JAMA Dermatology, JAMA Dermatology, 2025 -- Highlights and Developments from 2025
- JAMA Internal Medicine, JAMA Internal Medicine— The Year in Review, 2025
- JAMA Neurology, JAMA Neurology Year in Review, 2025
- Atopic dermatitis clinical guideline, American Academy of Dermatology, 2025
- JAMA Cardiology — JAMA Cardiology Year in Review, 2025
- Atopic dermatitis clinical guideline
- Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials - ScienceDirect
- ESMO Diagnosis, Treatment and Follow-up of Cutaneous Melanoma Guideline Summary - Guideline Central
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
